title: Steroid Pulse Therapy for Blood Cell Recovery in Allogeneic Hematopoietic Stem Cell Transplantation.
abstract: OBJECTIVE
  Steroid pulse therapy is used to relieve pancytopenias in our hospital and is effective in some patients. However, it is unclear which patients will benefit from such therapy. Thus, we retrospectively analyzed the clinical features of patients undergoing allogeneic hematopoietic stem cell transplantation who received steroid pulse therapy to facilitate recovery in their blood cell counts.
  
  
  METHODS
  Between 2004 and 2012, 24 patients underwent steroid pulse therapy and the medical records of 17 of these evaluable patients (11 men, 6 women) were retrospectively reviewed. Bone marrow smears were assessed to calculate the proportion of hemophagocytic macrophages just prior to receiving pulse therapy.
  
  
  RESULTS
  Steroid pulse therapy was started at a median of 15 days after transplantation (range, 10-28 days). The median white blood cell count was 0.02×10(3)/μL (range, 0.01-0.4×10(3)/μL). Eight patients responded to pulse therapy and subsequent engraftment was achieved in all responders. None of the patients who underwent cord blood transplantation responded to the pulse therapy. Among the non-responders, only two patients achieved engraftment and four of nine non-responders died within one month. When evaluating the efficacy of steroid pulse therapy according to the ferritin level and proportion of hemophagocytic macrophages among patients undergoing bone marrow or peripheral blood stem cell transplantation, both values were higher in responders than in non-responders.
  
  
  CONCLUSIONS
  We speculate that responders have a hemophagocytic syndrome which is responsive to steroid pulse therapy. Thus, our results imply that the use of ferritin levels in combination with the proportion of hemophagocytic macrophages may be useful for the early detection of potential hemophagocytic syndrome after hematopoietic stem cell transplantation.
authors.affiliation: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Murata
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kudo
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kakihana
authors.forename: Kumiko
authors.initials: K
authors.lastname: Abe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Noriko
authors.initials: N
authors.lastname: Doki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
mesh_terms: D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001773:Blood Cells / Q000276:immunology*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000276:immunology / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D020551:Pulse Therapy, Drug; D012189:Retrospective Studies
chemical_list: D005938:Glucocorticoids